RESEARCH

I have more than 20 yrs of experience in the development of novel therapeutic strategies for mCRPC. In addition to drug development, I have expertise in the development and generation of advanced animal models, and alternative approaches for assessing therapeutic efficacy and safety, including novel models of liver metastasis and patient-derived xenografts (PDXs) and organoids (PDOs). Indeed, over the last decade we have developed and characterized >15 new PDXs derived from metastatic lesions in mCRPC patients. Many of these PDXs/PDOs/PDXOs represent emerging highly aggressive treatment-resistant phenotypes that are underrepresented in other prostate cancer PDX collections and thus, represent a valuable and unique resource that we share openly with other investigators.

My laboratory routinely performs biochemical assays related to target inhibition and enzyme kinetics, genetic manipulation for target validation, analysis of standard pharmacokinetic and pharmacodynamic (PK/PD) parameters to assess biodistribution, clearance, and target engagement, in addition to in vivo efficacy and toxicity using state-of-the-art and clinically-representative models such as those described above. I have an established track-record of productivity and history of collaboration with leaders not only at Johns Hopkins, but also leading academic centers and biopharmaceutical companies nationally and worldwide to facilitate efficient translation of promising therapeutic strategies from the preclinical space to the bedside. We maintain close relationships with our medical oncology colleagues to maximize translational potential and clinical relevance.